Celltrion (068270.KS), South Korea's largest biosimilar drugmaker, completed the cancellation of 488,977 treasury shares on June 4, a retirement worth roughly ₩100 billion ($73 million) that took effect through a change listing on the Korea Exchange, according to ETNews. The move trimmed shares outstanding to about 221.63 million, or a reduction of roughly 0.2 percent of the share count.
The individual cancellation is small. What matters to investors is what it confirms: management's stated plan to retire a cumulative ₩2 trillion ($1.46 billion) of stock this year is now all but locked in. Newspim and Hankyung report the company has decided on an additional ₩100 billion treasury buyback, already in progress, that it intends to cancel before year-end, which would carry total 2026 cancellations to approximately ₩2 trillion.
How big is ₩2 trillion for Celltrion?
Against a market capitalization of about ₩42.13 trillion (roughly $30.8 billion) as of May 29, per KRX market data, a ₩2 trillion cancellation equals close to 4.7 percent of the company's equity value retired in a single year. That places it, in the words of the company, at "the maximum level of shareholder return" among Korean pharmaceutical and biotech names, a characterization reported by Newspim.
The ₩2 trillion figure is credible precisely because most of it is already done. On April 1, 2026, Celltrion retired 9.11 million shares worth ₩1.72 trillion (about $1.26 billion), the largest cancellation in its history and one that, the Korea Herald reported, exceeded the combined ₩1.6 trillion of cancellations carried out across 2024 and 2025. That single action equaled roughly 4 percent of outstanding shares. The June 4 retirement and the additional ₩100 billion buyback now in motion are the increments that close the gap to ₩2 trillion.
Viewed over a longer horizon, Newspim reports Celltrion has cancelled approximately 18.56 million shares over the past three years, equivalent to about 8.4 percent of the current share count. Alongside the cancellations, the company has layered on a free share grant of roughly 10.92 million shares and ₩200 billion of additional purchases split evenly between the company and its largest shareholder, per Newspim.
The earnings backdrop
The buyback program rests on improving fundamentals rather than balance-sheet financial engineering alone. Celltrion posted record first-quarter results for 2026: revenue of ₩1.145 trillion ($840 million), up 36.0 percent year over year, and operating profit of ₩321.9 billion ($236 million), up 115.4 percent, for an operating margin of 28.1 percent, according to Seoul Economic Daily. The company attributed the gains to global sales of newer biosimilar products and said it is expanding its portfolio from 11 marketed products toward 18 by 2030.
Reducing the share base directly lifts earnings per share, an effect the company explicitly cited, telling Korean outlets that the cancellations reflect "confidence in firm fundamentals and future growth" while it pursues "shareholder returns expansion and business competitiveness strengthening simultaneously" (Newspim).
What to watch next
The specific data point that confirms the ₩2 trillion thesis is the cancellation of the additional ₩100 billion buyback the company says is underway; completion before year-end would finalize the cumulative total. Beyond that, second-quarter 2026 results, due in the summer, will show whether the 28.1 percent operating margin and triple-digit profit growth that underpin the return policy are holding.
Celltrion shares closed at ₩192,900 on May 29, within a 52-week range of ₩156,000 to ₩251,000, per Yahoo Finance and KRX data.
This article is for informational purposes only and does not constitute investment advice. Figures are sourced from company disclosures and the cited news outlets as of publication. Currency conversions use an approximate rate of 1 USD = 1,370 KRW unless otherwise noted.
